Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular in the treatment of diseases or disorders associated to increased relative to physiological or desired RhoJ/Cdc42 levels of expression or function.

Abstract: An image signal indicative of the head pose of a person in a scene, as provided by a camera may be processed by estimating, as a function of the image signal received by the image sensor, the head pose of the person. A view frustum of the person may be generated from the estimated head pose. A visual frustum of attention or VFOA of the person may be generated from the view frustum. From the visual frustum, a predicted movement trajectory of the person or an estimated scene attention map as a function of the visual frustum of attention, preferably by identifying in the attention map at least one object to be controlled may be generated.

Abstract: The present invention refers to a new multilayered material, reinforced with fibres and having an improved adhesion between the layers throughout its entire structure; to a process for its preparation and to the articles made with such material, intended to be exposed to adverse conditions, such as strong winds, stretching, temperature changes, such as for example sails for boat.

Abstract: A foot for a robotic exoskeleton includes three rigid foot segments, namely a middle foot segment arranged to be connected to a leg of the robotic exoskeleton, a front foot segment elastically connected to the front end of the middle foot segment by a first set of leaf springs and a rear foot segment elastically connected to the rear end of the middle foot segment by a second set of leaf springs. The foot has laces for fastening the foot to a person's shoe. In the condition where the front foot segment and the rear foot segment are both in contact with the ground, and no load is applied onto the foot, the middle foot segment is not in contact with the ground, but is elastically suspended by the first and second sets of springs.

Abstract: An electromagnetic actuator comprising a moving armature (41) comprising a pin (43) and a permanent magnet arrangement (45) arranged coaxially with the pin (43) and secured to it, and an excitation coil arrangement (42) arranged coaxially with the pin (43). The coil arrangement (42) is suppliable with a current to cause a movement of the movable armature (41). The actuator further comprises a surface (51) of ferromagnetic material. The permanent magnet arrangement (45) is axially interposed between the surface (51) of ferromagnetic material and the excitation coil arrangement (42). The permanent magnet arrangement (45) comprises a plurality of permanent magnet regions (45a) arranged around the pin (43) of the moving armature (41), wherein each permanent magnet region (45a) has a polarity opposite to the polarities of the permanent magnet regions (45a) angularly adjacent thereto. The excitation coil arrangement (42) comprises a coil having a lobed shape.

Abstract: A process for the manufacture of biodegradable plastic films in aqueous environment, starting from vegetal wastes in powder form is provided, without use in any steps of the process of chemical reagents and organic solvents that may leave harmful residues in the film, and without making use of operative conditions potentially compromising the environmental sustainability and an effortless scalability of the process.

Abstract: The driving system comprises: a first support structure; a second support structure supported by the first support structure for rotation about a stationary axis of rotation; a first actuation unit having a first motor device and a first output member; and a second actuation unit having a second motor device and a second output member. The first output member is drivingly connected with the second support structure for rotation about the first axis of rotation. The first motor device controls the rotation of the first output member, along with the second support structure, about the first axis of rotation. The second output member is supported by the second support structure for rotation about a second axis of rotation. The second motor device controls the rotation of the second output member about the second axis of rotation.

Abstract: Compounds of formula (I) in the capacity of compounds with anti-tumor activity for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).

Abstract: Lightening method of at least one biological sample (S), in which said at least one biological sample includes at least one or more fluorophores, at the focal point (F) of at least one objective lens (L) having a main optical axis (z-z), the method comprising the following operational steps:—lightening (step 10) said at least one biological sample (S) with at least one excitation beam (EB), which propagates between said at least one objective lens (L) and said at least one biological sample (S) along at least one first propagation axis (a-a);—lightening (step 20) said at least one biological sample (S) with at least two depletion beams (DB, DB?), which propagate between said at least one objective lens (L) and said at least one biological sample (S) along the respective second propagation axes (b-b, said depletion beams being donut-shaped, each one in a plane orthogonal to the respective second propagation axis (b-b, b?-b?); whereby said at least one first propagation axis (a-a) and said at least second propa

Abstract: The present invention refers to Amadoriase enzyme protein variants having de-glycating activity and improved thermostability compared to the wild type Amadoriase. The present invention refers also to the use of the thermostabilized Amadoriase as deglycating agent, preferably in the food industry. Moreover, the present invention refers to the use of the thermostabilized Amadoriase as diagnostic and/or therapeutic tools. Preferably, the Amadoriase enzyme protein variants of the invention can be used for determining the level of glycated haemoglobin in a biological sample and therefore for monitoring diabetes.

Abstract: The invention relates to a class of 5-carboxamide-2-thiobarbituric acid derivatives which inhibits human type II topoisomerase (topoII) enzyme and to use thereof as medicaments especially for blocking the proliferation of cancer cells and treating cancer. The invention also provides a method for the manufacture of the 5-carboxamide-2-thiobarbituric acid derivatives.

Abstract: A grasper device for mini-invasive surgery procedures is provided, having two jaws, each of which having two elastically-deformable elements fixed one another and developing according to a main longitudinal direction, in particular a front element which contacts the tissue to be grasped and a back support element receiving a grasping force from a proximal command and having a higher modulus of elasticity than the front element. During the application of a grasping force Fz, the two elements deform along a transverse direction that is orthogonal to the main longitudinal direction and to the grasping force Fz.

Abstract: The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

Abstract: Disclosed is a method for detecting the presence, progression or risk of onset of neurodegenerative disease, based on determination of the concentration of lipid markers in an individuals serum or plasma sample.

Abstract: The present invention refers to a process for the preparation of a graphene dispersion comprising the following steps: i) providing cellulose acetate flakes or powders; ii) swelling the cellulose acetate flakes or powders in an alcohol having from 1 to 3 carbon atoms; iii) adding acetic anhydride in a concentration range from 30 to 50 wt % referred to the total weight of the mixture; iv) adding graphene nanoplatelets to yield a graphene dispersion. The graphene dispersion is used as ink for composite materials that are employed in the field of foldable electronics. The invention relates also to a composite material comprising uniformly dispersed graphene nanoplatelets and its use for manufacturing electronic devices.

Abstract: An artificial hand is provided. The artificial includes phalanges suitable to reproduce at least one finger, hinges hinging a first element identifying a phalanx to a second element identifying a second phalanx, and an implementation mechanism suitable to command a reciprocal rotation between the hinges defining a mutual rotation speed between the first and second element. The hinges define different damping coefficients so that, during a mutual rotation of the first and second element, they are subject to distinct damping forces opposing mutual rotation and proportional to the mutual rotation speed so as to vary the movement of the artificial hand as a function of the mutual rotation speed.

Abstract: The present invention relates to a compound of formula (1): or an analogue thereof or a pharmaceutically acceptable salt thereof, for use in the treatment of a brain tumor, wherein the compound is administered intranasally and relative pharmaceutical compositions.

Abstract: A lighting system including a set of lighting devices for lighting an environment that may be controlled by a method. The method may include receiving, from one or more image sensors (e.g. a RGB-D camera—W), an image signal including a sequence of images of the environment under different conditions of illumination and light reflection. The method may further include processing the image signal to provide a light source identification signal representative of light sources affecting the environment, and controlling the lighting devices as a function of the light source identification signal, and, possibly, of human occupancy and activity.

Abstract: Method for detecting the presence of nucleases in a sample, characterized in that it comprises the steps of: —incubating the sample to be tested for the presence of nucleases with at least one oligonucleotide linker constituting the substrate for the nuclease to be detected, for a sufficient time to cause degradation of said oligonucleotide linker by the nuclease possibly present in the sample, —adding to the sample, upon incubation, colloidal gold nanoparticles comprising gold nanoparticles functionalized with a first probe oligonucleotide and gold nanoparticles functionalized with a respective second probe oligonucleotide, said first and second probe oligonucleotides being complementary to a respective portion of the nucleotide sequence of the oligonucleotide linker, and—examining the possible colour change of the sample as a result of the addition of said nanoparticles, a colour change of the sample to the colour assumed by the colloidal gold particles when aggregated at a distance less than their size bei

Abstract: Pharmaceutical compounds are disclosed having a bicyclic-sulphonamide structure of Formula 1: wherein R1 represents an unsubstituted or a substituted heteroaryl ring; R2, R3, R4, and R5 are independently selected from hydrogen, alkyl, hydroxyalkyl, and alkyl-O-alkyl, provided that either R2 and R3, or R4 and R5 are linked or taken together to form a bridge between the carbon atoms to which R2 and R3, or R4 and R5 respectively are directly linked, whereby the N-containing ring in Formula 1 is an azabicyclo moiety. The compounds and compositions including the compounds may be used in therapy as brain-cell-death protectants, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).